Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 20 January 2026 - 24 January 2026

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer shares fell 1.9% to $25.62 Friday as the stock went ex-dividend, nearly matching the $0.43 payout. The drop outpaced the health-care sector, with Moderna tumbling over 7% and Merck down 1%. Policy changes under Health Secretary Robert F. Kennedy Jr. have unsettled vaccine makers. Pfizer reports quarterly results and hosts a webcast on Feb. 3.
23 January 2026
·····
Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly shares fell 1.1% to $1,075.78 after Novo Nordisk’s new Wegovy pill logged over 18,000 U.S. prescriptions in its first full week. Investors are watching ahead of Lilly’s Feb. 4 earnings and an expected FDA decision on its own oral obesity drug by April. Several Lilly directors recently received stock units through a deferral plan.
23 January 2026
····
Johnson & Johnson stock today: Why JNJ can’t break out as talc risk shadows upbeat 2026 outlook

Johnson & Johnson stock today: Why JNJ can’t break out as talc risk shadows upbeat 2026 outlook

Johnson & Johnson shares traded nearly flat at $218.59 by late Friday morning as Wall Street upgrades met renewed worries over federal talc lawsuits. A special master recommended allowing plaintiffs’ experts to testify that J&J talc products can cause ovarian cancer, affecting over 67,500 cases. The company reported Q4 sales up 9.1% to $24.6 billion and projected 2026 sales of up to $101 billion.
23 January 2026
··
India’s Q3 results rush: IndusInd Bank profit seen plunging as JSW Steel, BPCL, Cipla report today

India’s Q3 results rush: IndusInd Bank profit seen plunging as JSW Steel, BPCL, Cipla report today

Over 50 Indian companies, including IndusInd Bank, JSW Steel, BPCL, and Cipla, will report December-quarter earnings on Friday. Brokerages expect IndusInd Bank’s profit after tax to drop sharply, with forecasts ranging from 13 crore to 313 crore rupees. JSW Steel faces weaker prices, while BPCL may see higher EBITDA due to softer crude. Pharma and banking sectors remain under pressure.
23 January 2026
······
GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK shares rose 0.1% in early London trading as investors assessed the $2.2 billion acquisition of RAPT Therapeutics and changes to ViiV Healthcare’s ownership. The deal brings ozureprubart, a mid-stage food-allergy drug, into GSK’s pipeline. Pfizer will exit ViiV, with Shionogi raising its stake to 21.7%. Uncertainty over U.S. vaccine policy clouds the outlook ahead of GSK’s Feb. 4 results.
22 January 2026
···
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares rose 0.8% to $25.73 Wednesday after the company agreed to exit its ViiV Healthcare stake, with Shionogi paying $1.875 billion and raising its holding to 21.7%. Pfizer also secured rights to Novavax’s Matrix-M adjuvant for $30 million upfront. Both deals await regulatory clearance and do not guarantee near-term earnings growth. Investors await Pfizer’s Q4 results on Feb. 3.
21 January 2026
····
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals shares fell 8% to $19.68 in premarket trading Wednesday after announcing a $150 million stock-and-warrant offering. The drop follows a 167% surge Tuesday on positive Phase 1 data for soquelitinib in atopic dermatitis. Corvus paused its $100 million at-the-market share sales facility ahead of the new deal. No severe adverse events were reported in the trial.
21 January 2026
···
GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK’s U.S.-listed shares fell 1.2% to $47.65 premarket after it agreed to buy RAPT Therapeutics for $2.2 billion, paying a 65% premium for rights to a mid-stage food allergy drug. The deal, led by new CEO Luke Miels, comes as GSK faces pressure to offset losses from expiring HIV drug patents. Pfizer will exit the ViiV Healthcare joint venture, with Shionogi raising its stake to 21.7%.
21 January 2026
···
Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix Pharmaceuticals shares fell 7.7% to A$10.61 at Wednesday’s close after the company reported unaudited FY2025 revenue in line with guidance and noted early momentum for Gozellix. China’s drug regulator accepted the Illuccix application, triggering a formal review. Investors weighed ongoing U.S. regulatory developments and recent clinical trial results.
21 January 2026
··
Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals shares soared over 167% to $21.41 in after-hours trading Tuesday after reporting positive placebo-controlled trial results for its experimental eczema pill. The company launched a $150 million underwritten stock and warrant offering following the data release. Analysts raised price targets. About 84 million shares changed hands.
21 January 2026
··
Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead Sciences shares slipped 0.2% to $124.68 Tuesday, outperforming a broader market drop. Bernstein reiterated its Outperform rating and $135 target, citing Yeztugo as a key 2026 driver. Florida announced steep cuts to its AIDS Drug Assistance Program, drawing criticism from advocates and raising concerns over HIV drug access.
20 January 2026
··
1 … 9 10 11 12 13 … 38

Stock Market Today

  • How Investors Can Buy SpaceX Stock Pre-IPO: 3 Key Options
    April 11, 2026, 5:11 AM EDT. SpaceX has confidentially filed for its IPO with the SEC, targeting a $1.75 trillion valuation and a potential $75 billion raise. Trading could start by July following a June roadshow. Investors unable to wait can gain exposure through three routes. The Ark Venture Fund offers 17% exposure but carries risks: a 2.9% expense ratio, limited quarterly liquidity, and heavy private company holdings. The Baron Partners Fund, with 33% SpaceX, boasts a 741% return over 10 years and allows more liquidity but focuses on fewer stocks. These funds provide pre-IPO opportunities but differ in risk and access. Retail investors eyeing SpaceX shares ahead of the blockbuster IPO should weigh fund structures, costs, and liquidity carefully.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 5:13 AM EDT How Investors Can Buy SpaceX Stock Pre-IPO: 3 Key Options April 11, 2026, 5:11 AM EDT. SpaceX has confidentially filed for its IPO with the SEC, targeting a $1.75 trillion valuation and a potential $75 billion raise. Trading could start by July following a June roadshow. Investors unable to wait can gain exposure through three routes. The Ark Venture Fund offers 17% exposure but carries risks: a 2.9% expense ratio, limited quarterly liquidity, and heavy private company holdings. The Baron Partners Fund, with 33% SpaceX,
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop